Teva Pharmaceutical Industries (TEVA) Set to Announce Earnings on Wednesday
Teva Pharmaceutical Industries (TEVA) Set to Announce Earnings on Wednesday
Teva Pharmaceutical Industries (NYSE:TEVA – Get Rating) will be releasing its earnings data before the market opens on Wednesday, February 8th. Analysts expect Teva Pharmaceutical Industries to post earnings of $0.64 per share for the quarter. Teva Pharmaceutical Industries has set its FY22 guidance at $2.40-$2.60 EPS.Investors that wish to listen to the company's conference call can do so using this link.
Teva制药工业公司(纽约证券交易所代码:Teva-GET评级)将在2月8日星期三市场开盘前公布其收益数据。分析师预计,Teva制药工业公司本季度每股收益为0.64美元。Teva制药工业公司已将其22财年的指引定为2.40-2.60美元EPS.希望收听该公司电话会议的投资者可以使用此链接进行收听。
Teva Pharmaceutical Industries (NYSE:TEVA – Get Rating) last issued its earnings results on Thursday, November 3rd. The company reported $0.56 earnings per share for the quarter, missing the consensus estimate of $0.58 by ($0.02). Teva Pharmaceutical Industries had a positive return on equity of 26.97% and a negative net margin of 8.52%. The firm had revenue of $3.60 billion during the quarter, compared to analysts' expectations of $3.86 billion. On average, analysts expect Teva Pharmaceutical Industries to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.
Teva制药工业公司(纽约证券交易所代码:Teva-GET评级)最近一次发布收益报告是在11月3日星期四。该公司公布本季度每股收益为0.56美元,低于普遍预期的0.58美元(0.02美元)。Teva制药工业公司的股本回报率为正26.97%,净利润率为负8.52%。该公司本季度营收为36亿美元,高于分析师预期的38.6亿美元。分析师平均预计,Teva制药工业本财年每股收益为2美元,下一财年为2美元。
Teva Pharmaceutical Industries Stock Up 2.7 %
Teva制药工业公司股价上涨2.7%
Shares of NYSE TEVA opened at $10.54 on Wednesday. Teva Pharmaceutical Industries has a 12-month low of $6.78 and a 12-month high of $11.44. The company has a market cap of $11.71 billion, a P/E ratio of -9.09 and a beta of 1.19. The company has a current ratio of 0.99, a quick ratio of 0.66 and a debt-to-equity ratio of 1.94. The stock has a fifty day moving average price of $9.57 and a 200 day moving average price of $9.16.
周三,纽约证交所Teva的股价开盘报10.54美元。Teva制药工业的12个月低点为6.78美元,12个月高位为11.44美元。该公司市值为117.1亿美元,市盈率为-9.09,贝塔系数为1.19。该公司的流动比率为0.99,速动比率为0.66,债务权益比率为1.94。该股的50日移动均价为9.57美元,200日移动均价为9.16美元。
Analyst Ratings Changes
分析师评级发生变化
Institutional Investors Weigh In On Teva Pharmaceutical Industries
机构投资者看好Teva制药工业
Several hedge funds and other institutional investors have recently made changes to their positions in TEVA. Ensign Peak Advisors Inc grew its stake in shares of Teva Pharmaceutical Industries by 14.9% in the 3rd quarter. Ensign Peak Advisors Inc now owns 54,450 shares of the company's stock worth $439,000 after acquiring an additional 7,050 shares in the last quarter. Weiss Multi Strategy Advisers LLC bought a new position in shares of Teva Pharmaceutical Industries in the first quarter worth approximately $393,000. United Services Automobile Association bought a new position in Teva Pharmaceutical Industries during the second quarter valued at approximately $371,000. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp grew its position in Teva Pharmaceutical Industries by 16.3% during the first quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp now owns 39,322 shares of the company's stock valued at $369,000 after acquiring an additional 5,500 shares during the last quarter. Finally, Atria Wealth Solutions Inc. purchased a new stake in shares of Teva Pharmaceutical Industries during the first quarter valued at approximately $285,000. 50.39% of the stock is owned by institutional investors.
几家对冲基金和其他机构投资者最近改变了他们在Teva的头寸。Ensign Peak Advisors Inc.在第三季度增持了Teva制药工业的股份14.9%。Ensign Peak Advisors Inc.在上个季度额外收购了7,050股后,现在拥有54,450股该公司股票,价值439,000美元。Weiss多策略顾问公司在第一季度购买了Teva制药工业的新头寸,价值约39.3万美元。联合服务汽车协会在第二季度购买了Teva制药工业的一个新头寸,价值约37.1万美元。不列颠哥伦比亚省投资管理公司第一季度在Teva制药工业的头寸增加了16.3%。不列颠哥伦比亚省投资管理公司在上个季度增持了5,500股后,现在拥有39,322股该公司股票,价值36.9万美元。最后,Atria Wealth Solutions Inc.在第一季度购买了Teva制药工业公司的新股份,价值约28.5万美元。50.39%的股票由机构投资者持有。
Teva Pharmaceutical Industries Company Profile
Teva制药工业公司简介
(Get Rating)
(获取评级)
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams.
Teva制药工业有限公司是一家制药公司,在北美、欧洲和国际上开发、制造、营销和分销仿制药、特种药和生物制药产品。该公司提供各种剂型的无菌产品、激素、高效药物和细胞毒性物质,包括片剂、胶囊、注射剂、吸入剂、液体、透皮贴片、软膏和乳膏。
Featured Stories
专题报道
- Get a free copy of the StockNews.com research report on Teva Pharmaceutical Industries (TEVA)
- Verizon, Charter Trend Higher In Past Month: Are They Buys Now?
- Dividend King Sysco: Buying On The Dip
- Is the 1,600% Rise in Genius Group Stock Justified?
- After Further Review, Investors Liked Exxon Mobil's Earnings
- Will Caterpillar Dig Its Way To Another Buying Opportunity?
- 免费获取StockNews.com关于Teva制药工业(Teva)的研究报告
- Verizon,Charge在过去的一个月里趋势更高:他们现在购买吗?
- 股利之王Sysco:逢低买入
- 天才集团股票1600%的涨幅合理吗?
- 在进一步审查后,投资者喜欢埃克森美孚的收益
- 卡特彼勒会挖出另一个收购机会吗?
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.
接受Teva制药工业日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Teva制药工业和相关公司的最新新闻和分析师评级的每日简要摘要。